| 1 |
31398712 | ANNIVERSARY REVIEW: Octreotide, 40 years later. | 2019 Nov |
1 |
| 2 |
29876704 | CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold? | 2018 Dec |
3 |
| 3 |
28454229 | Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. | 2017 Mar |
1 |
| 4 |
26430956 | New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. | 2015 May |
1 |
| 5 |
26537065 | Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors. | 2015 Sep-Oct |
1 |
| 6 |
19842996 | From somatostatin to octreotide LAR: evolution of a somatostatin analogue. | 2009 Dec |
4 |
| 7 |
17684767 | Peptide receptor expression in GEP-NET. | 2007 Aug |
1 |
| 8 |
16455627 | Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. | 2006 Feb |
1 |
| 9 |
22479715 | 18F-Fluoroethyl triazole-βAG-[(d)-Phe1-c(Cys2-Tyr3-(d)-Trp4-Lys5-Thr6-Cys7)Thr8] | 2004 |
1 |
| 10 |
11061606 | Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. | 2000 Sep |
1 |
| 11 |
8395752 | Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. | 1993 Jul-Aug |
1 |
| 12 |
2281708 | [The effect of octreotide on hormones of the GEP system (gastro-entero-pancreatic)]. | 1990 Sep |
1 |